W. Bensen
About
W. Bensen is a scholar working on Rheumatology, Genetics and Orthopedics and Sports Medicine.
According to data from OpenAlex, W. Bensen has authored 74 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Rheumatology, 15 papers in Genetics and 14 papers in Orthopedics and Sports Medicine. Recurrent topics in W. Bensen's work include Rheumatoid Arthritis Research and Therapies (27 papers), Systemic Lupus Erythematosus Research (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). W. Bensen is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (27 papers), Systemic Lupus Erythematosus Research (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). W. Bensen collaborates with scholars based in Canada, United States and France. W. Bensen's co-authors include Jonathan D. Adachi, Anthony B. Hodsman, Xavier Chevalier, A. D. Beaulieu, Francis X. Burch, Damien Lœuille, Thierry Conrozier, Simon Carette, David Silver and Philippe Goupille and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.
In The Last Decade
W. Bensen
71 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| W. Bensen Canada | 26 | 1.3k | 880 | 828 | 779 | 611 | 74 | 3.4k | ||
| B Mazières France | 27 | 1.6k 1.2× | 474 0.5× | 557 0.7× | 1.2k 1.5× | 278 0.5× | 145 | 3.0k | ||
| Chad Deal United States | 27 | 919 0.7× | 217 0.2× | 1.5k 1.8× | 527 0.7× | 1.1k 1.9× | 62 | 3.9k | ||
| Gert Hein Germany | 29 | 1.2k 0.9× | 172 0.2× | 529 0.6× | 387 0.5× | 349 0.6× | 113 | 2.9k | ||
| L. Sinigaglia Italy | 33 | 832 0.6× | 179 0.2× | 1.5k 1.8× | 499 0.6× | 778 1.3× | 99 | 3.6k | ||
| D. Choquette Canada | 32 | 3.1k 2.3× | 522 0.6× | 547 0.7× | 1.3k 1.7× | 158 0.3× | 99 | 4.1k | ||
| Gyula Poór Hungary | 26 | 564 0.4× | 195 0.2× | 761 0.9× | 455 0.6× | 473 0.8× | 97 | 2.2k | ||
| Riccardo Melicòni Italy | 33 | 1.6k 1.2× | 368 0.4× | 135 0.2× | 341 0.4× | 347 0.6× | 137 | 3.5k | ||
| Ombretta Di Munno Italy | 29 | 554 0.4× | 221 0.3× | 1.2k 1.5× | 374 0.5× | 640 1.0× | 58 | 2.6k | ||
| E. Martín‐Mola Spain | 44 | 4.2k 3.2× | 576 0.7× | 275 0.3× | 658 0.8× | 413 0.7× | 113 | 6.0k | ||
| Ombretta Viapiana Italy | 38 | 1.4k 1.0× | 161 0.2× | 1.6k 1.9× | 445 0.6× | 1.0k 1.7× | 234 | 4.6k |
Countries citing papers authored by W. Bensen
Since
Specialization
Citations
This map shows the geographic impact of W. Bensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Bensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Bensen more than expected).
Fields of papers citing papers by W. Bensen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by W. Bensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Bensen. The network helps show where W. Bensen may publish in the future.
Co-authorship network of co-authors of W. Bensen
This figure shows the co-authorship network connecting the top 25 collaborators of W. Bensen. A scholar is included among the top collaborators of W. Bensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Bensen. W. Bensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rahman, Proton, D. Choquette, W. Bensen, et al.. (2016). Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open. 6(4). e009661–e009661.
2.
Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2016). Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.. PubMed. 34(3). 489–99.
3.
Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2015). Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders. 16(1). 176–176.
4.
Beattie, Karen, W. Bensen, Raja Bobba, et al.. (2015). Assessing the Reliability of a Semiautomated Segmentation Algorithm for Quantifying Erosions in the Metacarpophalangeal Joints of Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 42(9). 1582–1586.
5.
Thorne, Carter, W. Bensen, D. Choquette, et al.. (2014). Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a Canadian Multicenter Prospective Observational Registry. Arthritis Care & Research. 66(8). 1142–1151.
6.
Alten, Rieke, M. Galeazzi, Hanns‐Martin Lorenz, et al.. (2014). SAT0245 Decreased Use of Glucocorticoids in PTS with RA Who Initiated IV Abatacept and Previously Failed at Least One Biologic Agent: Results from the 2-Year Action Study. Annals of the Rheumatic Diseases. 73. 681–681.
7.
Beattie, Karen, W. Bensen, Raja Bobba, et al.. (2014). A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. Trials. 15(1). 268–268.
8.
Bensen, W., A. Jovaisas, Carter Thorne, et al.. (2013). SAT0035 Variability in the Classification of Remission among Disease Activity Indices and Their Correlation: An Analysis From a Prospective, Observational Registry. Annals of the Rheumatic Diseases. 72. A591–A592.
9.
Reginster, Jean‐Yves, R. Chapurlat, H K Genant, et al.. (2011). EFFICACY AND SAFETY OF STRONTIUM RANELATE IN THE TREATMENT OF KNEE OSTEOARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INTERNATIONAL TRIAL. Osteoporosis International. 22.
10.
Karsh, Jacob, Edward Keystone, Boulos Haraoui, et al.. (2011). Canadian Recommendations for Clinical Trials of Pharmacologic Interventions in Rheumatoid Arthritis: Inclusion Criteria and Study Design: Table 1.. The Journal of Rheumatology. 38(10). 2095–2104.
11.
Chevalier, Xavier, Philippe Goupille, A. D. Beaulieu, et al.. (2009). Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis Care & Research. 61(3). 344–352.
12.
Adachi, Jonathan D., Αλεξάνδρα Παπαϊωάννου, George Ioannidis, et al.. (2005). Evaluation of easily measured risk factors in the prediction of osteoporotic fractures. BMC Musculoskeletal Disorders. 6(1). 47–47.
13.
Bensen, W.. (2002). Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. British journal of rheumatology. 41(9). 1008–1016.
14.
McClung, Michael R., Richard Eastell, W. Bensen, et al.. (2000). Risedronate reduces hip fracture risk in elderly women with osteoporosis. Open Repository and Bibliography (University of Liège).
15.
Goldstein, Jay L., et al.. (2000). Development of a scoring system for predicting upper gastrointestinal distress. Gastroenterology. 118(4). A249–A249.
16.
Bensen, W., Thomas Burke, Robert Makuch, et al.. (2000). Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.. PubMed. 27(8). 1876–83.
17.
Adachi, Jonathan D., Mary Bell, W. Bensen, et al.. (1997). Fluoride therapy in prevention of rheumatoid arthritis induced bone loss.. PubMed. 24(12). 2308–13.
18.
Bellamy, Nicholas, W. Bensen, A. D. Beaulieu, et al.. (1995). A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis.. PubMed. 22(5). 915–20.
19.
Tugwell, Peter, Claire Bombardier, Michael Gent, et al.. (1990). Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. The Lancet. 335(8697). 1051–1055.
20.
Denburg, Judah A., et al.. (1977). Megaloblastic anemia in patients receiving total parenteral nutrition without folic acid or vitamin B12 supplementation.. PubMed. 117(2). 144–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by B Mazières Breakdown of academic impact, for papers by Chad Deal Breakdown of academic impact, for papers by Gert Hein Breakdown of academic impact, for papers by L. Sinigaglia Breakdown of academic impact, for papers by D. Choquette Breakdown of academic impact, for papers by Gyula Poór Breakdown of academic impact, for papers by Riccardo Melicòni Breakdown of academic impact, for papers by Ombretta Di Munno Breakdown of academic impact, for papers by E. Martín‐Mola Breakdown of academic impact, for papers by Ombretta Viapiana